An Amgen migraine drug developed to head off pain before it starts has won FDA approval, the first for a new class of preventive drug candidates for the condition.
The Amgen (NASDAQ: AMGN) drug, erenumab (Aimovig), is a subcutaneous injection given once a month. The drug blocks the receptor for calcitonin gene-related peptide (CGRP), a protein released by neurons that is thought to play a role in the start of migraine pain. In contrast to triptans, an older group of medications that patients take at the onset of pain, these CGRP drugs are meant to stop the activity that leads… Read more »
UNDERWRITERS AND PARTNERS